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INTRODUCTION
Adenoviral (ADV) infections have increasingly been rec-
ognized as a cause of morbidity and mortality in patients with
immunologic deﬁciencies [1,2], especially following hemato-
poietic stem cell transplantation (HSCT) [3,4]. The incidence
of cytomegalovirus (CMV) infection has diminished in
HSCT recipients due to effective prophylactic antiviral thera-
pies, and ADV infections have emerged as a major viral
pathogen [2,4-6]. Epidemiologic studies have shown that
pediatric patients who are recipients of matched unrelated
donor HSCT or who have graft-versus-host disease (GVHD)
are at increased risk of developing ADV infections [2,3,7-10].
It is uncertain at present whether ADV infections in HSCT
recipients are due to reactivation of latent virus, donor
derived acquisition, or horizontal transmission [11].
The clinical manifestations of ADV infections in HSCT
recipients range from asymptomatic excretion to dissemi-
nated disease with multiorgan failure and death. Many
infected recipients have clinical disease, including hemor-
rhagic cystitis, gastroenteritis, pneumonitis, hepatitis, and
encephalitis [2,8,9]. Isolating virus from ≥2 sites has been
found to correlate with invasive disease and an unfavorable
clinical outcome [2,6]. Recent reports of mortality rates
have ranged from 7.7% to 38% [4,7-9]. At present, no
proven antiviral therapy is available for the treatment of ADV.
However, ribavirin, ganciclovir, vidarabine, intravenous (IV)
immunoglobulin, and adoptive immunotherapy/leukocyte
transfusions have been administered empirically to ADV-
infected immunocompromised patients, including HSCT
recipients [9,11-21].
Cidofovir (CDV), a nucleoside and phosphonate ana-
logue, is a broad-spectrum anti-DNA viral agent [22]. The
active intracellular diphosphate form of the drug exerts its
mechanism of action as both a competitive inhibitor and an
alternative substrate for 2′-deoxycytidine 5′-triphosphate in
the viral DNA polymerase reaction. CDV has been shown to
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ABSTRACT
Adenoviral (ADV) infections are increasingly recognized as a cause of morbidity and mortality in pediatric hemato-
poietic stem cell transplantation (HSCT). We reviewed our experience with ADV infections in HSCT patients
hospitalized for transplantation at Childrens Hospital Los Angeles January 1998 through December 1998. ADV
was detected in 47% of patients, with recipients of HSCT from alternative donors (matched unrelated, unrelated
cord, and mismatched related donors) being more frequently culture positive than recipients of HSCT from
matched siblings (62% versus 27%, P = .04). Detection of ADV from 2 or more sites was associated with organ
injury, eg, hemorrhagic cystitis, enteritis, and hepatitis. Because of the high incidence of ADV culture–positive
patients and the lack of effective anti-ADV therapy, we initiated a prospective trial to evaluate cidofovir (CDV) in
the treatment of ADV infections in HSCT recipients. Eight patients were enrolled on a dosage schedule of
1 mg/kg 3 times weekly. All of these patients eventually achieved long-term viral suppression and clinical improve-
ment, although 6 patients needed prolonged CDV therapy for up to 8 months before CDV could be stopped with-
out ADV recurrence. We did not observe dose-limiting nephrotoxicity, and the discontinuation of the drug was not
required in any patients. Prospective controlled trials to further define the role of CDV in the treatment of ADV
infections in HSCT patients are warranted.
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be curative in a preclinical model of ocular ADV in rabbits
[23], and case reports have demonstrated some success in the
treatment of disseminated ADV in immunocompromised
patients (eg, HSCT recipients and acquired immune defi-
ciency syndrome patients) [24,25] at the dosage of 5 mg/kg
per week. The therapy had to be discontinued in 1 patient
due to renal toxicity [24]. The dose-limiting toxicity of intra-
venous CDV, given at the recommended dosage of 5 mg/kg
once a week, is nephrotoxicity, including an elevation in the
serum creatinine levels and/or acute renal failure, proteinuria,
and renal Fanconi syndrome with tubular acidosis. The con-
comitant use of IV hydration and probenecid can prevent or
decrease the severity of adverse renal events. Probenecid
decreases renal clearance of CDV by the active inhibition of
renal tubule secretion. This action increases the serum levels of
CDV and decreases its urinary concentration, thus improving
its bioavailability and protecting the renal tubules [26]. Other
side effects associated with the use of CDV include neutrope-
nia and ocular toxicity (anterior uveitis, iritis, hypotony).
Pediatric patients with disseminated ADV infection
treated with CDV at a dosage of 1 mg/kg 3 times a week
became culture negative with the resolution of symptoms
after 2 to 3 weeks of therapy (R. Whitley, oral communica-
tion, June 1999). This dosage was chosen in an attempt to
reduce the renal toxicity associated with the previous dosing
regimen (5 mg/kg once weekly) in a group of patients likely
to have compromised renal function at the onset. We, there-
fore, initiated a prospective open-label trial evaluating the
role of CDV at a dosage of 1 mg/kg 3 times a week for the
treatment of ADV infections in HSCT recipients.
MATERIALS AND METHODS
Two studies are described in this article, a retrospective
review of our experience with ADV in HSCT recipients (Jan-
uary 1998 through December 1998) followed by a prospec-
tive trial to evaluate CDV in the treatment of ADV infections
in HSCT recipients (June 1999-December 2000). For both
studies, organ injury and disease attributed to ADV was based
on consistent clinical symptoms with positive cultures (pneu-
monitis, hemorrhagic cystitis, encephalitis), or, in the absence
of positive cultures from the site of disease, multiple sites pos-
itive for ADV and the absence of another deﬁned pathogen
(enteritis, hepatitis, bone marrow suppression).
Review of ADV Infections in HSCT Recipients
A retrospective chart review of allogeneic HSCT recipi-
ents who were hospitalized from January through December
1998 was performed. The following data were collected: (1)
demographic features (age at time of HSCT, sex), (2) under-
lying lymphohematologic disease, (3) type of HSCT: alter-
native donors (AD) (matched unrelated, unrelated cord, and
mismatched related donors) or matched related donors
(MRD), (4) sites of ADV culture positivity, (5) time to ﬁrst
positive ADV culture, (6) associated organ injury, and (7)
clinical outcome (Tables 1-3).
CDV Treatment of ADV Infections 
A prospective open study was performed to evaluate
CDV administration in HSCT recipients with positive ADV
cultures (June 1999-December 2000). The protocol was
approved by the Committee for Clinical Investigations of the
hospital Institutional Review Board. Written informed con-
sent was obtained from the parent or legal guardian of each
recipient before enrollment into the study. The inclusion cri-
teria were (1) recipients of AD HSCT with positive ADV
cultures from any site, (2) recipients of histocompatible
HSCT with positive blood cultures or positive cultures from
2 or more sites, or (3) any HSCT recipient with positive
cultures and clinical evidence of ADV infection, such as
hemorrhagic cystitis, pneumonia, hepatitis, or enteritis. The
exclusion criteria were (1) hypersensitivity to probenecid
and/or cidofovir and (2) age younger than 3 months.
The treatment regimen consisted of CDV, 1 mg/kg
per day 3 times a week for 9 doses. Probenecid, 1.25 g/m2
Table 1. Underlying Diseases for Which Hematopoietic Stem Cell 
Transplantations Were Performed*
Underlying Diagnosis No. of Patients
Acute lymphoblastic leukemia 12
Severe combined immunodeficiency 5
Acute nonlymphoblastic leukemia 4
Severe aplastic anemia 3
Wiskott-Aldrich syndrome 3
Non-Hodgkin’s lymphoma 2
Chronic myelogenous leukemia 2
X-linked lymphoproliferative disorder 1
Chronic granulomatous disease 1
CD40 ligand deficiency 1
Fanconi’s anemia 1
Juvenile chronic myelogenous leukemia 1
Total 36
*Retrospective review of adenoviral infections in hematopoietic
stem cell transplant recipients from January 1998 to December 1998.
Table 2. Adenovirus Cultures in Hematopoietic Stem Cell Transplant
Recipients*
No. of hematopoietic stem cell transplantations 36
No. of patients with positive adenoviral 17 (47)
cultures (%)
Median day of first positive culture (range) Day 35 
(day –10 to day 257)
No. of positive cultures on admission (%) 3 (8)
Sites of positive cultures
Urine 14
Blood 12
Respiratory 10
Cerebrospinal fluid 1
Stool/rectal 3
Type of hematopoietic stem cell transplantation 
with positive cultures
AD (%) 13/21 (62)†
MRD (%) 4/15 (27)
*Retrospective review of adenoviral infections in hematopoietic
stem cell transplant recipients. AD indicates alternative donor
(matched unrelated, unrelated cord, or mismatched related); MRD,
matched related donor.
†Corrected chi-square test, 4.24; P = .04.
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by mouth, was given 3 hours before and 1 and 8 hours after
CDV administration. IV hydration at 3 times maintenance
was initiated 1 hour before and continued until 1 hour after
the completion of the CDV infusion, followed by hydration
at 2 times maintenance for an additional 2 hours after CDV
infusion. Recipients were initially treated with 9 doses. In
patients whose cultures remained positive while on CDV or
became positive after cessation of CDV therapy, CDV was
instituted for an additional 9-dose course and then contin-
ued on varying schedules until ADV cultures became sterile
(Tables 4 and 5).
Patients were cultured for ADV from nasopharyngeal
wash and/or throat, urine, stool, and blood at the time of
admission for transplantation or when clinically indicated, and
weekly thereafter. Previously positive sites were cultured prior
to subsequent doses of CDV. When clinically indicated, other
sites (bronchoalveolar lavage and small-bowel and colon
endoscopy biopsies) were cultured. Creatinine clearance and
glomerular ﬁltration rate were obtained prior to initiation of
CDV and at the completion of therapy. Drug toxicity was
monitored with serum creatinine, urine protein, complete
blood count with differential, and a chemistry panel.
Detection of Adenovirus 
Adenovirus was detected using a shell-vial culture
method [27]. Blood was collected in heparin or EDTA
tubes, and a buffy coat was prepared and washed with sterile
phosphate-buffered saline. Respiratory tract specimens were
mixed with Hanks’ balanced salt solution, vortexed, and, if
necessary, centrifuged to remove particulate material. Urine
specimens were inoculated directly or brieﬂy centrifuged if
turbid. Stool or rectal swabs were placed in viral transport
medium and centrifuged in the case of the former or vor-
texed for the later. The viral transport media were then used
for inoculation. Two shell vials with a monolayer of A549
cells were inoculated with 0.2 to 0.3 mL each of processed
specimen. The vials were incubated for 16 to 24 hours and
checked for toxicity. Incubation was continued for 40 to
48 hours, and the first vial was stained using an indirect
immunofluoresence antibody assay with mouse anti-
adenovirus monoclonal antibodies (ViroMed, Minneapolis,
MN). The second shell vial was stained after 5 days of incu-
bation if the ﬁrst vial was negative. The stained cells were
examined by ﬂuorescence microscopy for cells with nuclei
or nuclear-cytoplasmic staining.
Statistical Analyses 
Differences between groups were assessed by chi-square
or Student t test, with P values of <.05 considered signiﬁcant,
Table 3. Clinical Outcomes of Patients With Positive Adenovirus Cultures
(N = 17)*
Outcome No. of Patients (%)
Organ dysfunction
1 positive site 0/7 (0)
≥2 positive sites 10/10† (100)
Bone marrow suppression‡ 11 (65)
Graft-versus-host disease 5 (29)
Hemorrhagic cystitis 6 (35)
Enteritis 3 (18)
Hepatitis 2 (12)
Pneumonitis 2 (12)
Encephalitis 1 (6)
Deaths attributable to adenovirus infection 2/17 (12)
Encephalitis 1
Hemorrhagic cystitis/pneumonitis 1
*Retrospective review of adenoviral infections in hematopoietic
stem cell transplant recipients.
†P < .01, Fisher exact test (2-tailed).
‡Not explained by other causes.
Table 4. Characteristics of Hematopoietic Stem Cell Transplant Recipients Treated With Cidofovir*
GVHD Status at Day of Sites of
Patient Age at Type of HSCT GVHD Time of Initial Initial Initial Positive
No. Diagnosis HSCT HSCT Conditioning Prophylaxis Positive ADV culture Culture ADV Culture
544 Aplastic anemia 8 y 1 mo AD CTX, ATG, TLI CSA, MTX, ATG Chronic skin and GI 540 U, TH
583 Hereditary lympho- 10 mo AD CTX, BU, VP16 CSA, MTX, ATG –11 U, TH, N, S, BAL
histiocytosis
597 Acute lymphoblastic 6 y 11 mo MRD TBI, ATG, VP16 MTX –20 B 
leukemia
610 Acute lymphoblastic 7 y 7 mo AD (cord) CTX, ATG, TBI CSA, MPS Chronic skin and GI 44 U
leukemia
616 Aplastic anemia 14 y 8 mo AD CTX, ATG, TLI CSA, MTX, ATG Acute and chronic 21 B
622 Myelodysplastic 3 y 1 mo AD CTX, ATG, BU CSA, MTX, ATG –5 U, NP
syndrome
637 Chronic myelogenous 6 y 9 mo AD CTX, ATG, BU CSA, MTX, ATG Chronic skin and GI 52 U, TH
leukemia
651 Chronic myelogenous 10 y 8 mo MRD CTX, BU CSA, MTX 53 U, B 
leukemia
*HSCT indicates hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; ADV, adenovirus; AD, alternative donor; CTX,
cytoxan; ATG, antithymocyte globulin; TLI, total lymphocyte irradiation; CSA, cyclosporine A; MTX, methotrexate; GI, gastrointestinal; U, urine;
TH, throat; BU, busulfan; VP16, etoposide; N, nasopharyngeal; S, stool; BAL, bronchoalveolar lavage; MRD, matched related donor; TBI, total
body irradiation; B, blood; MPS, methylprednisolone.
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using EpiInfo version 6 (Centers for Disease Control and
Prevention, Atlanta, GA).
RESULTS
Incidence of ADV in HSCT Recipients
During the period from January through December
1998, 36 patients who received HSCT for lymphohemato-
logic disease were hospitalized. Table 1 details the underly-
ing diseases for which HSCT were performed. Twenty-one
patients received HSCT from AD and 15 from MRD. The
median patient age was 5.5 years (range, 3 months-19 years)
with a male:female ratio of 21:15. Table 2 describes the
ADV isolations. In 1998, 17 (47%) of 36 HSCT recipients
developed positive ADV cultures from time of admission for
transplantation through hospital discharge. Three of
17 patients had positive cultures at the time of admission
and were clinically asymptomatic. When patients receiving
AD HSCT were compared with patients receiving MRD
HSCT, 62% of AD HSCT recipients had positive ADV cul-
tures, whereas only 27% of MRD HSCT recipients had
positive ADV cultures (P = .04; corrected chi-square, 4.24).
Table 3 details the patients’ outcomes in terms of morbidity
and mortality. All 10 patients with ≥2 positive culture sites
for ADV developed organ dysfunction, whereas none (0/7)
of the patients with only 1 positive site developed organ dys-
function (P < .01). Concomitant bone marrow suppression
(11 patients) unexplained by other causes (ganciclovir
administration or other infections) and GVHD (5 patients)
were associated with the development of ADV infection.
There were 4 deaths in these patients, 2 of which were
directly attributable to ADV infection: 1 from encephalitis
and 1 from hemorrhagic cystitis/pneumonitis.
The Use of CDV in the Treatment of ADV
Eight recipients undergoing HSCT, 6 AD and 2 MRD,
with positive ADV cultures were enrolled in a phase II trial
of CDV. Table 4 describes the patient characteristics; 3 of
8 patients were ADV culture positive at the time of admis-
sion for transplantation. Two of the 3 pre-HSCT patients
were symptomatic (pneumonia) and had multiple sites of
ADV positivity. The third patient was asymptomatic, but
had a positive blood culture. Additionally, 2 of 3 were to
receive unrelated donor HSCT. All 3 patients were treated
when culture results became available because, according to
our experience from the previous year, the risk of dissemi-
nated disease due to ADV was very high, especially in the
setting of an unrelated donor HSCT. The remaining
5 patients developed positive ADV cultures after HSCT
(range, day 21-540). Positive ADV cultures were initially
detected in urine (1), blood (2), nasopharyngeal wash/urine
(1), throat/urine (2), urine/blood (1) and stool/bronchoalve-
olar lavage/urine/throat (1).
The clinical and virologic outcomes of patients receiv-
ing CDV are detailed in Table 5. Five of 8 recipients were
ADV culture negative at the end of the initial 9 doses of
CDV. The remaining 3 recipients remained ADV culture
positive and continued to receive CDV therapy for an addi-
tional 9 doses. Three of the 5 patients, who had initially
become culture negative, developed positive ADV cultures
after the discontinuation of CDV, and CDV therapy was
reinstituted; 2 of these patients received 2 additional courses
(9 doses per course), and 1 received 1 additional course. All
3 patients who had ADV recurrences were receiving therapy
for established GVHD. Overall, 6 of 8 patients had persis-
tent positive ADV cultures or recurrence and required fur-
ther CDV after completion of the initial course of CDV
Table 5. Clinical and Virologic Outcomes of Patients Receiving Cidofovir*
Culture Status Pre-CDV Post-CDV
Patient Clinical Disease After Initial New Sites Cx Recurrence Duration of BUN/CR BUN/CR
No. Attributable to ADV 9 doses of CDV Positive (on CDV) (off CDV)† Therapy (mg/dL) (mg/dL) Current Status
544 Febrile illness, enteritis, Negative Yes 3 mo‡ 23/0.6 26/0.7 Alive, 
GVHD exacerbation Cx negative
583 Pneumonia Negative No 3 wk 22/0.2 14/0.2 Deceased 8 mo
post-HSCT§
597 Asymptomatic Positive No 6 wk 14/0.4 26/0.6 Deceased 5 mo
post-HSCT§
610 Enteritis, febrile illness, Negative Blood, gastrointestinal Yes 8 mo‡ 18/0.6 8/1.1 Alive,
conjunctivitis, GVHD (colon), nasopharyngeal Cx negative
exacerbation 
616 Febrile illness, hemorrhagic Negative Blood Yes 5 mo‡ 58/1.2 15/1.1 Alive, 
cystitis, GVHD exacerbation Cx negative
622 Pneumonia, ARDS Positive Blood No 2.5 mo 21/0.4 6/0.4 Alive, 
Cx negative
637 Febrile illness, enteritis, Negative No 3 wk 9/0.4 15/0.3 Alive, 
GVHD exacerbation Cx negative
651 Hemorrhagic cystitis Positive No 2 mo‡ 11/0.6 8/0.5 Alive,
Cx negative
*ADV indicates adenovirus; CDV, cidofovir; Cx, adenoviral culture; BUN, blood urea nitrogen; CR, creatinine; GVHD, graft-versus-host 
disease; ARDS, acute respiratory distress syndrome.
†Virologic and/or clinical recurrence after stopping CDV.
‡Patient required CDV 1 to 2 times per week for up to 3 months for suppression of disease and/or positive cultures.
§Death unrelated to ADV infection.
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therapy. Three of 8 patients had new sites of ADV culture
positivity while receiving CDV therapy. After the comple-
tion of multiple (2-3) courses of CDV, 4 of 8 recipients
required ongoing CDV therapy, administered 1 to 2 times
weekly for up to an additional 3 months, to suppress viral
production until immunologic recovery occurred.
All 8 patients in this study eventually became culture
negative with cessation of ADV-related disease and without
evidence of permanent ADV-related organ dysfunction.
Two patients treated with CDV died of causes unrelated to
ADV disease: 1 from sepsis/multiorgan failure and 1 from
the relapse of acute lymphoblastic leukemia.
None of the patients required the discontinuation of
CDV therapy for renal or other toxicities. Because of the
complex nature of these patients and administration of other
potentially nephrotoxic agents (eg, cyclosporin A, aminogly-
cosides), some patients did experience renal dysfunction (eg,
patient number 610, Tables 4 and 5), but it could not be
determined whether the dysfunction was directly attribut-
able to CDV alone. Many patients experienced gastroin-
testinal symptoms, particularly nausea, associated with
probenecid administration.
As previously reported, in addition to organ involve-
ment, eg, pneumonitis, hemorrhagic cystitis, caused by
ADV infection, the onset or exacerbation of acute and
chronic GVHD was associated with the onset of positive
ADV cultures. Three of the 4 patients who required long-
term CDV therapy to maintain an ADV culture–negative
status also required additional therapy to treat exacerbations
of GVHD (declizumab [Zenapax], mycophenolate mofetil
[Cellcept], and/or ATG [Atgam]).
DISCUSSION
In this retrospective study of pediatric patients hospitalized
for HSCT for lymphohematologic diseases, positive ADV cul-
tures were detected in 47% of recipients. Patients receiving
HSCT from AD were more frequently ADV-culture positive
than recipients of histocompatible transplants (62% versus
27%). Detection of ADV from 2 or more sites was associated
with invasive disease. Of the 4 deaths that occurred among
study patients, 2 were directly attributable to ADV disease.
The detection of ADV in patients before or shortly after they
undergo HSCT suggests that reactivation of latent virus may
be the source of replicating ADV in some patients [28,29].
At present there is no established therapy for ADV infec-
tions. Indeed, 2 recent retrospective reviews of the use of
intravenous ribavirin in adult HSCT recipients with invasive
ADV infection did not show appreciable beneﬁt [30,31]. In a
recent study using CDV at the standard recommended
dosage (5 mg/kg once a week), 3 of 7 pediatric patients expe-
rienced nephrotoxicity after the second dose of CDV, and
therapy was interrupted [32]. Two patients tolerated reintro-
duction of therapy, but 1 patient died of invasive ADV after
therapy was discontinued.
In our study, all 8 patients treated with CDV eventually
became culture negative after 3 weeks to 8 months of CDV
therapy. Since discontinuing therapy, all patients have
remained culture negative (2-10 months). The small number
of patients treated and the absence of a control group make
the determination of the signiﬁcance of these ﬁndings difﬁ-
cult. No deaths were attributable to ADV in patients receiv-
ing CDV, and sustained toxicity related to the use of CDV
was not documented. The initial response to CDV did not
predict the long-term response to therapy. Five of 8 patients
had an initial rapid response to CDV, becoming culture neg-
ative; only 1 of these patients had a durable response to CDV
therapy and required only 1 course of CDV. These results
suggest that, as in the case of herpes infections in HSCT
recipients, the long-term administration of antiviral therapy
will be required, presumably until the HSCT recipient
develops anti-ADV cellular immunity adequate to permit the
successful cessation of CDV therapy.
Three patients, each of whom had coexisting GVHD,
were treated with prolonged CDV therapy (range, 3-
8 months) to suppress viral excretion. The presence of viral
infection, most notably CMV, has long been recognized as a
risk factor for the development of GVHD in HSCT recipi-
ents [33-41]. Our data, and that of others, suggest that a sim-
ilar relationship may exist between ADV and GVHD
[1,2,7,10]. It has been postulated that acute GVHD in the
context of viral infections, such as those of the herpes group
and others, is initiated by donor-derived T lymphocytes with
reactivity to viral antigens expressed on host cells [42]. In
chronic GVHD, which is associated with CMV infections,
the development of autoantibodies to CD13, expressed on
keratinocytes, fibroblasts, endothelial cells, and macro-
phage/monocytes, appears to be associated with the develop-
ment of clinical disease [43]. Both acute and chronic GVHD
may involve local donor- and recipient-derived cytokines
(tumor necrosis factor α, interferon γ, interleukin [IL]-1α,
IL-6), leading to the pathologic changes in the skin and gas-
trointestinal system [42,43]. In addition, the presence of viral
infections may further suppress the immunocompetence of
the developing donor-derived immune system [41].
During 1998, patients who underwent HSCT at Chil-
drens Hospital Los Angeles (CHLA) experienced a high
incidence of ADV culture positivity, which was associated
with morbidity and mortality. The rate of ADV culture posi-
tivity at CHLA was higher than that published in other pedi-
atric reports [7,8,10]. Ongoing studies are needed to deﬁne
the epidemiology of ADV infections in pediatric HSCT
recipients. Major limitations in the present study include the
absence of a prospective control group and the inability to
determine the serotypes, which would be helpful in the char-
acterization of the epidemiology of ADV infections. In addi-
tion, the absence of histopathologic support for some clinical
deﬁnitions of illness attributed to ADV, speciﬁcally enteritis
and hepatitis, may have led to an overestimation of ADV dis-
ease. In this study, shell-vial assay was used for detection of
ADV; other diagnostic tools (ie, quantitative nucleic acid
ampliﬁcation techniques) [44,45] should be investigated to
determine their role in the diagnosis of ADV disease. Earlier
and quantitative ADV detection may aid in the investigation
of the response to new prophylactic and therapeutic inter-
ventions, as has been the case for CMV infection [46-50].
In the present study, CDV on the dosage schedule of
1 mg/kg per day administered 3 times weekly appeared to be
well tolerated. In view of the pathogenic potential of ADV in
HSCT recipients, prospective controlled trials to deﬁne fur-
ther the role of CDV in the treatment of ADV infections in
HSCT recipients should be considered.
Adenovirus and Cidofovir in HSCT
393B B & M T
ACKNOWLEDGMENTS
The authors wish to thank Clark B. Inderlied, PhD,
Clinical Microbiology Laboratory, Childrens Hospital Los
Angeles, for adenoviral cultures; Kathy Wilson, RN, and
Renna Kellen, RN, for assistance in conducting this study;
and Wilbert H. Mason, MD, MPH, for statistical support.
In addition, we thank the nursing and medical staff of the
Bone Marrow Transplant Unit, Childrens Hospital Los
Angeles, especially Robertson Parkman, MD, for critical
review of the manuscript.
REFERENCES
1. Foy HM. Adenoviruses. In: Evans AS, Karlow RA, eds. Viral
Infection of Humans: Epidemiology and Control. 4th ed. New York,
NY: Plenum Press; 1997:119-138.
2. Carrigan DR. Adenovirus infections in immunocompromised
patients. Am J Med. 1997;102:71-74.
3. Russell SJ, Vowels MR, Vale T. Haemorrhagic cystitis in paedi-
atric bone marrow transplant patients: an association with infec-
tive agents, GVHD and prior cyclophosphamide. Bone Marrow
Transplant. 1994;13:533-539.
4. Childs R. Sanchez C, Engler H, et al. High incidence of adeno-
and polyomavirus-induced hemorrhagic cystitis in bone marrow
allotransplantation for hematological malignancy following
T cell depletion and cyclosporine. Bone Marrow Transplant. 1998;
22:889-893.
5. Blanke C, Clark C, Brown R, et al. Evolving pathogens in allo-
geneic bone marrow transplantation: increased fatal adenoviral
infections. Am J Med. 1995;99:326-328.
6. Shields AF, Hackman RC, Fife KH, Corey L, Meyers JD. Aden-
ovirus infections in patients undergoing bone-marrow transplan-
tation. N Engl J Med. 1985;312:529-533.
7. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing inci-
dence of adenovirus disease in bone marrow transplant recipients.
J Infect Dis. 1994;169:775-781.
8. Hale GA, Heslop HE, Krance RA, et al. Adenovirus infection
after pediatric bone marrow transplantation. Bone Marrow Trans-
plant. 1999;23:277-282.
9. Howard DS, Phillips II GL, Reece DE, et al. Adenovirus infec-
tions in hematopoietic stem cell transplant recipients. Clin Infect
Dis. 1999;29:1494-1501.
10. Maltezou HC, Kafetzis DA, Abisaid D, Mantzouranis EC, Chan
KW, Rolston KVI. Viral infections in children undergoing hemato-
poietic stem cell transplant. Pediatr Infect Dis J. 2000;19:307-312.
11. Green M, Michaels MG. Adenovirus, parvovirus B19, and papil-
lomavirus. In: Bowden RA, Ljungman P, Paya CV, eds. Transplant
Infections. Philadelphia, Pa: Lippincott-Raven Publishers;
1998:287-294.
12. Miyamura K, Hamaguchi M, Taji H, et al. Successful ribavirin
therapy for severe adenovirus hemorrhagic cystitis after allogeneic
marrow transplant from close HLA donors rather than distant
donors. Bone Marrow Transplant. 2000;25:545-548.
13. Jurado M, Navarro JM, Hernandez J, Molina MA, DePablos JM.
Adenovirus-associated haemorrhagic cystitis after bone marrow
transplantation successfully treated with intravenous ribavirin.
Bone Marrow Transplant. 1995;15:651-652.
14. Kapelushnik J, Or R, Delukina M, Nagler A, Livni N, Engelhard D.
Intravenous ribavirin therapy for adenovirus gastroenteritis in
bone marrow transplantation. J Pediatr Gastroenterol Nutr.
1995;21:110-112.
15. Jurado CM, Hernandez MF, Navarro MJM, Ferrer CC, Escobar
VJL, De Pablos GJM. Adenovirus pneumonitis successfully treated
with intravenous ribavirin. Haematologica. 1998;83:1128-1129.
16. Cassano WF. Intravenous ribavirin therapy for adenovirus cystitis
after allogeneic bone marrow transplantation. Bone Marrow Trans-
plant. 1991;7:247-248.
17. Chen FE, Liang RH, Lo JY, Yuen KY, Chan TK, Peiris M.
Treatment of adenovirus-associated haemorrhagic cystitis with
ganciclovir. Bone Marrow Transplant. 1997;20:997-999.
18. Kawakami M, Ueda S, Maeda T, et al. Vidarabine therapy for
virus-associated cystitis after allogeneic bone marrow transplanta-
tion. Bone Marrow Transplant. 1997;20:485-490.
19. Kitabayashi A, Hirokawa M, Kuroki J, Nishinari T, Niitsu H,
Miura AB. Successful vidarabine therapy for adenovirus type 11-
associated acute hemorrhagic cystitis after allogeneic bone mar-
row transplantation. Bone Marrow Transplant. 1994;14:853-854.
20. Chakrabarti S, Collingham KE, Fegan CD, Pillay D, Milligan
DW. Adenovirus infections following haematopoietic cell trans-
plantation: is there a role for adoptive immunotherapy? Bone Mar-
row Transplant. 2000;26:305-307.
21. Hromas R, Cornetta K, Srour E, Blanke C, Broun ER. Donor
leukocyte infusion as therapy of life-threatening adenoviral infec-
tions after T-cell-depleted bone marrow transplantation. Blood.
1994;84:1689-1690.
22. De Clercq E. In search of a selective antiviral chemotherapy. Clin
Microbiol Rev. 1997;10:674-693.
23. Oliveira CBR, Stevenson D, LaBree L, McDonnell PJ, Trousdale
MD. Evaluation of cidofovir (HPMPC, GS-504) against aden-
ovirus type 5 infection in vitro and in a New Zealand rabbit ocu-
lar model. Antiviral Res. 1996;31:165-172.
24. de Sevaux RGL, Kullberg BJ, Verweij PE, van de Nes JAP, Meis
JFGM, van der Meer JWM. Adenovirus cholecystitis in a patient
with AIDS. Clin Infect Dis. 1998;26:997-999.
25. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Suc-
cessful treatment of adenovirus disease with intravenous cidofovir
in an unrelated stem-cell transplant recipient. Clin Infect Dis.
1999;28:690-691.
26. Hardman JG, Limbird LE, eds. Goodman & Gilman’s The Pharma-
cological Basis of Therapeutics. 10th ed. New York, NY: McGraw-
Hill; 1996:651-652.
27. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds.
Manual of Clinical Microbiology. 7th ed. Washington, DC: Ameri-
can Society of Microbiology Press; 1999:997-982.
28. Hierholzer JC. Adenoviruses in the immunocompromised host.
Clin Microbiol Rev. 1992;5:262-274.
29. Singh-Naz N, Rodriguez W. Adenoviral infections in children.
Adv Ped Infect Dis. 1996;11:365-388.
30. La Rosa AM, Champlin RE, Mirza N, et al. Adenoviral infections
in adult recipients of blood and marrow transplants. Clin Infect
Dis. 2001;32:871-876.
31. Bordigoni P, Carret A-S, Venard V, Witz F, Le Faou A. Treat-
ment of adenovirus infections in patients undergoing allogeneic
hematopoietic stem cell transplantation. Clin Infect Dis. 2001;32:
1290-1297.
32. Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of ade-
novirus infection and treatment with cidofovir after bone mar-
row transplantation in children. Bone Marrow Transplant.
2001;27:621-626.
33. Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G.
Cytomegalovirus infection associated with and preceding chronic
graft-versus-host disease. Transplantation. 1984;38:465-468.
J.A. Hoffman et al.
394
34. Miller W, Flynn P, McCullough J, et al. Cytomegalovirus infec-
tion after bone marrow transplantation: association with acute
graft-versus-host disease. Blood. 1986;67:1162-1167.
35. Jacobsen N, Keiding N, Ryder L, et al. Graft-versus-leukaemia
activity associated with cytomegalovirus antibody positive bone mar-
row donors in acute myeloid leukaemia. Lancet. 1987;1:456-457.
36. Bostrom L, Ringden O, Sundberg B, Ljungman P, Linde A, Nils-
son B. Pretransplant herpesvirus serology and acute graft-versus-
host disease. Bone Marrow Transplant. 1989;4:547-552.
37. McCarthy AL, Malik P, Peiris JS, et al. Increase in severity of
graft versus host disease by cytomegalovirus. J Clin Pathol.
1992;45:542-544.
38. Einsele H, Ehninger G, Hebart H, et al. Incidence of local CMV
infection and acute intestinal GVHD in bone marrow transplant
recipients with severe diarrhea. Bone Marrow Transplant.
1994;14:955-963.
39. Matthes-Martin S, Aberle SW, Peters C, et al. CMV-viraemia
during allogeneic bone marrow transplantation paediatric
patients: association with survival and graft-versus-host-disease.
Bone Marrow Transplant. 1998;21(suppl 2):S53-S56.
40. Takemoto Y, Takatsuka H, Wada H, et al. Evaluation of
CMV/human herpes virus-6 positivity in bronchoalveolar lavage
fluids as early detection of acute GVHD following BMT: evi-
dence of significant relationship. Bone Marrow Transplant.
2000;26:77-81.
41. Appleton AL, Sviland L. Pathogenesis of GVHD: role of herpes
viruses. Bone Marrow Transplant. 1993;11:349-355.
42. Parkman R. Graft-versus-host disease and cytokines. Curr Opin
Hematol. 1993;1:223-227.
43. Parkman R. Chronic graft-versus-host disease. Curr Opin Hema-
tol. 1998;5:22-25.
44. Elnifro EM, Cooper RJ, Klapper PE, Bailey AS. PCR and restric-
tion endonuclease analysis for rapid identiﬁcation of human aden-
ovirus subgenera. J Clin Microbiol. 2000;38:2055-2061.
45. Echavarria MS, Ray SC, Ambinder R, Dumler JS, Charache P.
PCR detection of adenovirus in a bone marrow transplant recipi-
ent: hemorrhagic cystitis as a presenting manifestation of dissemi-
nated disease. J Clin Microbiol. 1999;37:686-689.
46. Einsele H, Ehninger L, Steidle M, et al. Polymerase chain reac-
tion to evaluate antiviral therapy for cytomegalovirus disease.
Lancet. 1991;338:1170-1172.
47. Zaia JA, Schmidt GM, Chao NJ, et al. Use of preemptive ganci-
clovir based solely on asymptomatic pulmonary cytomegalovirus
infection in marrow transplant recipients—long-term follow-up
[abstract]. Blood. 1994;84(suppl 10):249a.
48. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reac-
tion monitoring reduces the incidence of cytomegalovirus disease
and the duration and side effects of antiviral therapy after bone
marrow transplantation. Blood. 1995;86:2815-2820.
49. Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus
pp65 antigenemia-guided early treatment with ganciclovir versus
ganciclovir at engraftment after allogeneic bone marrow trans-
plantation: a randomized double-blind study. Blood. 1996;88:
4063-4071.
50. Ljungman P, Lore K, Aschan J, et al. Use of a semi-quantitative
PCR for cytomegalovirus DNA as a basis for pre-emptive antivi-
ral therapy in allogeneic bone marrow transplant patients. Bone
Marrow Transplant. 1996;17:583-587.
